Immutep (YP1A) Stock Overview
A clinical-stage biotechnology company, develops lymphocyte activation gene-3 (LAG-3) related immunotherapies for cancer and autoimmune diseases in Australia. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
YP1A Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
Immutep Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.28 |
| 52 Week High | AU$2.92 |
| 52 Week Low | AU$0.24 |
| Beta | 2.2 |
| 1 Month Change | -12.50% |
| 3 Month Change | -4.11% |
| 1 Year Change | -79.56% |
| 3 Year Change | -84.70% |
| 5 Year Change | -91.14% |
| Change since IPO | -95.36% |
Recent News & Updates
Recent updates
Shareholder Returns
| YP1A | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -4.8% | -0.8% | -1.8% |
| 1Y | -79.6% | -4.9% | 4.2% |
Return vs Industry: YP1A underperformed the German Biotechs industry which returned -8.6% over the past year.
Return vs Market: YP1A underperformed the German Market which returned 3.6% over the past year.
Price Volatility
| YP1A volatility | |
|---|---|
| YP1A Average Weekly Movement | 8.4% |
| Biotechs Industry Average Movement | 5.5% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 12.6% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: YP1A's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: YP1A's weekly volatility has decreased from 25% to 8% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1987 | n/a | Marc Voigt | www.immutep.com |
Immutep Limited, a clinical-stage biotechnology company, develops lymphocyte activation gene-3 (LAG-3) related immunotherapies for cancer and autoimmune diseases in Australia. The company's lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on the LAG-3 immune control mechanism for the treatment of cancer. Its product pipeline also includes AIPAC-003, which has completed an integrated Phase II/III clinical trial for the treatment of metastatic breast cancer; TACTI-003, which has completed a Phase IIb clinical trial to treat first line head and neck squamous cell carcinoma (1L HNSCC); an investigator-initiated Phase II trial evaluating neoadjuvant efti as monotherapy and in combination with chemotherapy prior to surgery in patients with early-stage HR+/HER2-negative breast cancer; and EFTISARC-NEO, which is in a Phase II clinical trial for the treatment of soft tissue sarcoma.
Immutep Limited Fundamentals Summary
| YP1A fundamental statistics | |
|---|---|
| Market cap | €51.05m |
| Earnings (TTM) | -€49.06m |
| Revenue (TTM) | €12.33m |
Is YP1A overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| YP1A income statement (TTM) | |
|---|---|
| Revenue | AU$19.93m |
| Cost of Revenue | AU$91.95m |
| Gross Profit | -AU$72.01m |
| Other Expenses | AU$7.29m |
| Earnings | -AU$79.30m |
Last Reported Earnings
Jun 30, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.054 |
| Gross Margin | -361.25% |
| Net Profit Margin | -397.83% |
| Debt/Equity Ratio | 0% |
How did YP1A perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/09/11 23:28 |
| End of Day Share Price | 2026/09/11 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2026/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Immutep Limited is covered by 14 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Melissa Benson | Barrenjoey Markets Pty Limited |
| Thomas Wakim | Bell Potter |
| Dylan Dupuis | B. Riley Securities, Inc. |